These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 1772981)

  • 1. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
    Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comeback of hirudin as an antithrombotic agent.
    Markwardt F
    Semin Thromb Hemost; 1991 Apr; 17(2):79-82. PubMed ID: 1771415
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
    Walenga JM; Pifarre R; Hoppensteadt DA; Fareed J
    Semin Thromb Hemost; 1989 Jul; 15(3):316-33. PubMed ID: 2688104
    [No Abstract]   [Full Text] [Related]  

  • 5. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hirudin as alternative anticoagulant--a historical review.
    Markwardt F
    Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of the anticoagulant hirudin: its biotechnological production and clinical practice.
    Sohn JH; Kang HA; Rao KJ; Kim CH; Choi ES; Chung BH; Rhee SK
    Appl Microbiol Biotechnol; 2001 Dec; 57(5-6):606-13. PubMed ID: 11778867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
    Raake W; Klauser RJ; Elling H; Zeiller P
    Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leeches to hirulogs and other thrombin-directed antithrombotics.
    Fenton JW
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1121-9. PubMed ID: 1400076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant and antithrombotic actions of recombinant hirudin.
    Kaiser B
    Semin Thromb Hemost; 1991 Apr; 17(2):130-6. PubMed ID: 1837615
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
    Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
    Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
    Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
    Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
    Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
    Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.
    Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK
    Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.